Dispute resolution is the US Food and Drug Administration’s preferred process for withdrawing accelerated approvals, a route that could dramatically speed up the slow and time-consuming exercise.
In its fiscal year 2023 budget congressional justification, the agency included several accelerated approval reforms among its legislative proposals, including revising the withdrawal procedure “so that FDA can follow...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?